


FIG.1

2/19

FIG. 2



3/19





FIG.3


8/19

FIG. 8



9/19

FIG. 9




12/19

FIG. 11B

Inhalation of OVA and decoy into rat




**Decoy : 2mg/4ml
OVA : 5%wt. x 5min
O2 flow 7-8 l/min**



nasal inhalation


13/19

Inhalation of decoy into rat




**Decoy :2 or 4mg/20ml x 2
Air flow 7-8 l/min, 60min
normal inhalation**

FIG.11C




Insertion of needle


FIG.14




4/19




5/19



6/19



7/19



10/19

FIG.10

Effect of double decoy in aortic aneurysm model rat




FIG.11A

Method

OVA
subcutaneous
injection



Day0

Day12

Day14

8,24hr

**after OVA
challenge**

OVA
subcutaneous
injection



Day0


Day12 & 13

Day14

24hr


**OVA
challenge**

FIG.12A
Eosinophil population and
cell count in BAL fluid
cell population
cell count



15/19


FIG.12B BAL cell count



16/19


BAL Eosinophil %

FIG.12C



17/19

FIG. 13A BAL Eosinophil cell count



18/19

FIG.13B BAL Eosinophil %

